Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
Aims: To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg.Methods: In a 12-week, double-blind trial, subjects with self-reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturit...
| Publicado en: | International Journal of Clinical Practice Vol. 68; no. 9; pp. 1065 - 1074 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | clinical trial research Journal Article |
| Publicado: |
Wiley-Blackwell
Sep2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |